A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial
Rosati G, Cella CA, Cavanna L, Codecà C, Prisciandaro M, Mosconi S, Luchena G, Silvestris N, Bernardini I, Casaretti R, Zoratto F, Amoroso D, Ciarlo A, Barni S, Cascinu S, Davite C, Di Sanzo A, Casolaro A, Bilancia D, Labianca R Gastric Cancer (2022), 25, 783–793
Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy
Nerviano, 7 February 2022 NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of the Health Commission of Lombardy Region, Mr. Loredano Pollegioni, Chairman of FRRB (Fondazione […]
NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries
Nerviano, 17 January 2022 The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos, Raj Sundar, Jianghua (Peter) Zhao, Liping Meng, and Massimiliano Amato. Dr. Dolgos joins from […]
Entrectinib, the kinase inhibitor drug invented and initially developed by Nerviano Medical Sciences won the Prix Galien Italia 2021 Award in the Chemically Synthesized Drugs category
Nerviano, 5 November 2021 Entrectinib, the kinase inhibitor drug that was invented and initially developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has won the Prix Galien Italia 2021 award as an antitumor therapy with agnostic indication in the category of Chemically Synthesized Drugs. […]
Nerviano Medical Sciences Receives FDA “Study May Proceed” Letter for First-In-Human Phase 1 Clinical Trial under Its Investigational New Drug Application for NMS-03602173, a Dual IDH1/2 Inhibitor, in Advanced Solid Tumors
Nerviano, 22 October 2021 Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a pharmaceutical company developing innovative new chemical entities (NCE) for the treatment of cancers, today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate NMS-03602173, a second-generation oral inhibitor of […]
NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor
Magnaghi P., Casuscelli F., Ardini E., Parazzoli A., Troiani S., Valsasina B., Texido G., Casale E., Avanzi N., Orsini P., Nuvoloni S., Salom B., Lombardi Borgia A., Salsi E., Saturno G., Re Depaolini S., Stellato C., Montagnoli A., Galvani A. and Isacchi A. 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; October 26 – […]
Development of an Effective Tumor-Targeted Contrast Agent for Magnetic Resonance Imaging Based on Mn/H-Ferritin Nanocomplexes
Tullio C, Salvioni L, Bellini M, Degrassi A, Fiandra L, D’Arienzo M, Garbujo S, Rotem R, Testa F, Prosperi D, Colombo M ACS Appl Bio Mater (2021), 15, 4(11), 7800-7810
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas
Vannata B, Vanazzi A, Negri M, Liptrott SJ, Bartosek A , Miani M , Di Sanzo A, Cavalli F, Zucca E, Stathis A Hematol Oncol (2021), 39(1), 60-65.
Development of an Effective Tumor-Targeted Contrast Agent for Magnetic Resonance Imaging Based on Mn/H-Ferritin Nanocomplexes
Tullio C, Salvioni L, Bellini M, Degrassi A, Fiandra L, D’Arienzo M, Garbujo S, Rotem R, Testa F, Prosperi D, Colombo M ACS Appl Bio Mater (2021), 15, 4(11), 7800-7810
Pharma Tech Outlook Names NMS Group a Top Drug Discovery and Development Solution Provider in Europe 2021
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue. The annual list showcases companies that are providing cutting-edge drug discovery and development tech solutions and services. Determined by a panel of experts […]